Application of beta-nicotinamide mononucleotide in preparation of preparation for promoting placenta angiogenesis of sows and feed
By adding β-nicotinamide single nucleotide to the sow's pregnancy diet, the placental blood vessel density and related gene expression were improved, and the problem of low placental blood vessel density affecting the performance of sows was solved, and the piglet's newborn weight was significantly improved Born quality.
Patent Information
- Application Number
- CN202411172851.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-08-26
AI Technical Summary
The low placental blood vessel density will affect the growth and development of embryos/fetals during pregnancy, resulting in a decrease in the primary weight of newborn piglets, an increase in morbidity and mortality. Whether NMN is between the placental blood vessel density of pregnant sows in the prior art. The relationship is unknown.
Adding β-nicotinamide single nucleotide to the pregnancy diet of sows can promote placental angiogenesis by increasing the placental blood vessel density and related gene expression, thereby increasing the number of live births, healthy litters, and newborn litters Both heavy and newborn individuals are heavy.
The number of live litters, number of healthy litters, weight of newborn litters and weight of newborn individuals was significantly improved, and the rate of weak litters was reduced. The β-nicotinamide mononucleotide was confirmed by placental HE staining and gene expression analysis. in promoting placental angiogenesis.
Smart Images

Figure CN118903177A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of feed, and specifically relates to application of beta-nicotinamide mononucleotide in preparing a preparation for promoting sow placental angiogenesis and feed. Background Art
[0002] Placental vascular density is directly related to the growth and development of the embryo / fetus or its organs during pregnancy in mammals. Too low placental vascular density will affect the birth weight of newborn piglets and will also have an adverse effect on their subsequent growth and development, such as increased morbidity and mortality, metabolic disorders, and decreased growth performance. Nicotinamide mononucleotide (NMN) is a naturally occurring biologically active nucleotide. NMN is a precursor of nicotinamide adenine dinucleotide (NAD+) and can be converted into NAD+ in mammals. NAD+ is also known as coenzyme I, and its full name is nicotinamide adenine dinucleotide. It is widely distributed in all cells and participates in thousands of biological catalytic reactions. It is an indispensable coenzyme. In the prior art, NMN has the effects of anti-aging and life extension, and is usually used in food additives and cosmetics, but it is unknown whether NMN is related to the placental vascular density of pregnant sows. Summary of the invention
[0003] In order to solve the technical problems existing in the above-mentioned background technology, the present invention provides the use of β-nicotinamide mononucleotide in preparing a preparation for promoting sow placental angiogenesis.
[0004] As a further illustration of the present invention, the β-nicotinamide mononucleotide can increase the number of piglets born alive, the number of healthy piglets born, the litter weight at birth, the average weight of newborn piglets, and reduce the rate of weak piglets.
[0005] The present invention also provides a feed for promoting sow placental angiogenesis, wherein the feed contains β-nicotinamide mononucleotide.
[0006] As a further illustration of the present invention, the feed is used to feed sows in gestation period.
[0007] As a further illustration of the present invention, the feed is used to feed sows from 70 days of gestation to the farrowing stage.
[0008] As a further illustration of the present invention, the amount of β-nicotinamide mononucleotide added to the sow's diet is 2 g-5 g / day.
[0009] Compared with the prior art, the present invention has the following beneficial technical effects: The β-nicotinamide mononucleotide provided by the present invention can significantly increase the number of live piglets, the number of healthy piglets, the weight of the newborn litter, and the average weight of the newborn individuals, and extremely significantly reduce the rate of weak piglets. The results of placental HE staining show that the addition of β-nicotinamide mononucleotide to the pregnancy diet significantly increases the placental vascular density. At the same time, through correlation analysis, it is found that the placental vascular density is significantly positively correlated with the weight of the newborn piglets. In addition, the addition of β-nicotinamide mononucleotide to the diet of pregnant sows significantly increases the expression of placental angiogenesis-related genes CD31, FLK1 and VEGF-A mRNA, indicating that β-nicotinamide mononucleotide plays an important role in promoting sow placental angiogenesis, thereby increasing the number of live piglets, the number of healthy piglets, the weight of the newborn litter, and the average weight of the newborn individuals. BRIEF DESCRIPTION OF THE DRAWINGS
[0010] FIG1 is a diagram of blood vessel density of a sow placenta provided by the present invention, wherein A is HE staining of the placenta, arrows indicate placental blood vessels, and B is the placental blood vessel density.
[0011] Figure 2 This is a correlation analysis diagram between placental vascular density and piglet birth weight provided by the present invention.
[0012] Figure 3 : is the placenta expression level graph provided by the present invention, wherein D is the placenta CD31 mRNA expression level, E is the placenta VEGF-A mRNA expression level, and F is the placenta FLK1 mRNA expression level. DETAILED DESCRIPTION
[0013] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention. Example 1
[0014] 1. Animal husbandry and management A total of 60 Landrace × Large White binary hybrid primiparous sows of similar age and weight were selected in this experiment and randomly divided into three treatment groups, with 20 sows in each treatment group and 1 sow in each replication. The control group (NC) was fed a basic pregnancy diet, the low-dose group (2g / d) added 2g / d NMN to the basic pregnancy diet, and the high-dose group (5g / d) added 5g / d NMN to the basic pregnancy diet. The experiment lasted for 44 days from 70 days of pregnancy to the end of delivery. The experimental sows were in estrus, mated at the same time, and delivered at the same time. During pregnancy, empty sows and sows returning to estrus were observed and eliminated from the experimental pig group. The final number of replications in each treatment group was 15 sows. The experimental sows were raised in single pens, and the temperature in the pig house was maintained at 18-22 ℃. During pregnancy, sows were fed a restricted feeding mode, that is, they were fed a gestation diet of 2.2 kg / d from 0 to 90 days of gestation and 2.5 kg / d from 91 to 114 days of gestation, and were fed at 7:30 am every day. Sows were free to eat and drink. During the experiment, all sows were able to finish the day's feed and no hunger strike occurred.
[0015] 2 Determination of sow reproductive performance On the day of sow farrowing, record the total number of piglets born, the number of live piglets, the number of healthy piglets, the number of weak piglets, the number of mummies and the number of stillbirths, and calculate the weak piglet rate of the sow. At the same time, weigh the newborn piglets and calculate the litter weight at birth. Piglets with a birth weight ≤0.9kg are recorded as weak piglets.
[0016] 3 Collection of placental samples On the day of sow farrowing, when the piglets are born, quickly clamp the umbilical cord at one end of the sow and the other end of the piglet with hemostats, tie cotton threads with labels (sterilized) at both ends of the umbilical cord, and then cut the umbilical cord in the middle, so that the cotton threads with labels can be retracted into the sow's body with the umbilical cord, so that the placenta can correspond to the piglets one by one after being discharged. After the sow farrows, the placenta is separated and weighed.
[0017] Collection of placental molecular biology samples: After the sow placenta is delivered, the placental membrane and connective tissue are peeled off, and 3 placental samples of about 5 g are cut from the same part of each placenta, placed in cryopreservation tubes, quickly frozen with liquid nitrogen and stored in a -80℃ refrigerator for subsequent indicator determination.
[0018] Placental morphology sample collection: After the sow placenta is delivered, the placental membrane and connective tissue are peeled off, and a 5*5 cm piece of umbilical cord is cut about 5 cm above the umbilical cord. 2 The placental tissue was stored in 4% paraformaldehyde for subsequent HE staining.
[0019] 4 Analysis of placental vascular density The placenta was embedded in 4% paraformaldehyde and sliced, and then stained with hematoxylin-eosin (HE). The stained slices were photographed under a microscope, and three fields of view were randomly selected for each slice. ImageJ was used to measure the placental vascular area and calculate the vascular density. The placental vascular density = total stromal layer vascular area / stromal layer area × 100%.
[0020] 5. Extraction of RNA from placental tissue The sample was taken out from the -80℃ refrigerator, 100 mg of tissue sample was accurately weighed, and the sample was washed with PBS solution to remove the blood stain on the surface. The washed sample was transferred to a mortar and frozen and ground with liquid nitrogen. The ground powder was quickly transferred to a pre-cooled centrifuge tube. The placental tissue RNA was extracted by lysis, precipitation, extraction, purification, washing, and drying according to the instructions of the Trizol reagent. After the concentration was determined by a micro-Nano Drop One spectrophotometer, an RNA sample with a total RNA concentration of 3000 ng was reverse transcribed to synthesize cDNA and stored in a -20℃ refrigerator for later use.
[0021] 6 Real-time fluorescence quantitative PCR 4 μL of 10-fold diluted cDNA, 5 μL of 2×PerfectStart@ Green qPCRSuperMix, 0.2 μL of upstream primer, 0.2 μL of downstream primer were added to a 96-well plate, and 0.6 μL of sterile water was used to make up to 10 μL / well. Two replicates were set for each sample, and B2M1 was used as the tissue internal reference for correction. The results were calculated using the 2-△△ct method. The primer sequences of each target gene were designed using NCBI primer design software and synthesized by Shanghai Shenggong Biotechnology Technology Service Co., Ltd. (Shanghai, China). The primer sequences used in the experiment are shown in Table 1.
[0022] Table 1 Primer sequences for fluorescence quantitative PCR Gene Forward Primer 5' to 3' Reverse Primer 5' to 3' VEGF-A ATGGCAGAAGGAGACCAGAA ATGGCGATGTTGAACTCCTC Ang 1 TTGGTCTTCATGCTGGGTCT GTGTTGACCTCTTTGCAGGG FLK 1 GATGCTCGCCTCCCTTTGA GAGTACGTGAAGCCGCTGTTG PLGF GGAGACGGTCAATGTCACCAT GAGAATGTCAGCTCCACGTAG CD31 CGAGGTCTGGGAACAAAGGG AGCCTTCCGTTCTAGAATATCTGTT B2M1 CAAGATAGTTAAGTGGGATCGAGAC TGGTAACATCAATACGATTTCTGA 7 Statistical methods After preliminary recording and processing of raw data using Excel, one-way analysis of variance (Oneway-ANOVA) was performed using SPSS 28 software. Values in the same row with different lowercase letters indicate significant differences (P < 0.05), and values in the same row with different uppercase letters indicate extremely significant differences (P < 0.01).
[0023] 8 Results When the sows gave birth, the piglets and placentas were weighed and statistically analyzed. The results showed that the addition of 2 g / d NMN to the gestation diet significantly increased the number of live piglets, the number of healthy piglets, the litter weight at birth, and the average weight of the piglets at birth (P<0.05), and the addition of 5 g / d NMN significantly increased the average weight of the piglets at birth (P<0.05). The addition of NMN to the gestation diet significantly reduced the number of weak piglets and the rate of weak piglets (P<0.05) (Table 3). The above results show that the addition of NMN to the gestation diet can significantly improve the reproductive performance of sows and improve the quality of sows.
[0024] Table 3 Effects of adding NMN to the gestation diet on reproductive performance of sows
[0025] After the sows gave birth, the placenta was collected and stored in 4% paraformaldehyde solution, embedded in paraffin and sliced, and HE and IF staining were performed. The experimental results showed that compared with the control group, the addition of NMN to the pregnancy diet significantly increased the placental vascular density (P < 0.01) (Figure 1 A, B). At the same time, correlation analysis found that the placental vascular density was significantly positively correlated with the individual weight of piglets at birth (P < 0.05) ( Figure 2 ). Fluorescence quantitative results showed that compared with the control group, the addition of NMN to the pregnancy diet significantly increased the expression of CD31, FLK1 and VEGF-A mRNA in the placenta (P < 0.05) ( Figure 3 DF).
[0026] It should be noted that, in this article, terms such as "comprises", "includes" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, article or apparatus that includes a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or apparatus.
[0027] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. Application of β-nicotinamide mononucleotide in the preparation of preparations for promoting sow placental angiogenesis.
2. The use of β-nicotinamide mononucleotide according to claim 1 in preparing a preparation for promoting sow placental angiogenesis, characterized in that: The β-nicotinamide mononucleotide can increase the number of piglets born alive, the number of healthy piglets, the litter weight at birth, the average weight of newborn piglets, and reduce the rate of weak piglets.
3. A feed for promoting sow placental angiogenesis, characterized in that: The feed contains β-nicotinamide mononucleotide.
4. The feed for promoting sow placental angiogenesis as claimed in claim 3, characterized in that: The feed is used for feeding sows in gestation period.
5. The feed for promoting sow placental angiogenesis as claimed in claim 3, characterized in that: The feed is used for feeding sows from gestation day 70 to farrowing stage.
6. The feed for promoting sow placental angiogenesis according to claim 3, characterized in that: The amount of β-nicotinamide mononucleotide added to the daily diet of sows is 2g-5g / day.
Citation Information
Patent Citations
Spermidine-containing feed for sows in middle and later periods of pregnancy as well as preparation method and application of feed
CN117814398A
Compositions and methods for enhancing bioenergetic status in female germ cells
US20130059384A1
Biological production of NAD precursors and analogs
US20160287621A1
Methods for increasing fertility
US20200368198A1
Cited By
Application of beta-nicotinamide mononucleotide in prevention and treatment of liver injury caused by aflatoxin B1
CN119818523A
